News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
22,025 Results
Type
Article (996)
Company Profile (1)
Press Release (21028)
Section
Business (11791)
Career Advice (13)
Deals (1466)
Drug Delivery (1)
Drug Development (2173)
FDA (347)
Job Trends (410)
News (14951)
Policy (547)
Tag
Academia (15)
Accelerated approval (2)
Allergies (4)
Alliances (859)
ALS (2)
Alzheimer's disease (11)
Antibody-drug conjugate (ADC) (2)
Approvals (356)
Artificial intelligence (3)
Autoimmune disease (3)
Bankruptcy (6)
Best Places to Work (329)
Biosimilars (2)
Biotechnology (1)
Bladder cancer (3)
Brain cancer (1)
Breast cancer (6)
Cancer (83)
Cardiovascular disease (3)
Career advice (12)
CAR-T (4)
Cell therapy (8)
Cervical cancer (1)
Clinical research (1967)
Collaboration (7)
Compensation (16)
Complete response letters (1)
COVID-19 (16)
C-suite (6)
Cystic fibrosis (2)
Data (149)
Depression (5)
Diabetes (12)
Diagnostics (178)
Digital health (2)
Drug discovery (1)
Drug pricing (1)
Duchenne muscular dystrophy (1)
Earnings (11055)
Events (1512)
Executive appointments (5)
FDA (494)
Frontotemporal dementia (2)
Funding (19)
Gene editing (2)
Gene therapy (6)
GLP-1 (24)
Government (32)
Guidances (109)
Healthcare (442)
IgA nephropathy (1)
Immunology and inflammation (9)
Immuno-oncology (2)
Indications (4)
Infectious disease (20)
Inflammatory bowel disease (3)
Influenza (3)
Intellectual property (3)
Interviews (1)
IPO (1029)
IRA (1)
Job creations (96)
Job search strategy (11)
Layoffs (13)
Leadership (1)
Legal (113)
Lung cancer (11)
Lymphoma (18)
Manufacturing (3)
MASH (4)
Medical device (499)
Medtech (503)
Mergers & acquisitions (442)
Metabolic disorders (27)
Multiple sclerosis (5)
Neurodegenerative disease (4)
Neuropsychiatric disorders (4)
Neuroscience (48)
NextGen: Class of 2026 (113)
Non-profit (32)
Obesity (8)
Opinion (2)
Ovarian cancer (1)
Pain (2)
Pancreatic cancer (2)
Parkinson's disease (8)
Patents (4)
Patient recruitment (8)
Peanut (3)
People (804)
Phase 1 (540)
Phase 2 (809)
Phase 3 (776)
Pipeline (442)
Policy (2)
Postmarket research (75)
Preclinical (162)
Press Release (1)
Prostate cancer (8)
Radiopharmaceuticals (6)
Rare diseases (8)
Real estate (111)
Regulatory (458)
Reports (2)
Research institute (14)
Resumes & cover letters (2)
Rett syndrome (1)
RNA editing (1)
Schizophrenia (7)
Series A (6)
Series B (2)
Sickle cell disease (1)
Spinal muscular atrophy (11)
Sponsored (1)
Startups (45)
Vaccines (10)
Weight loss (9)
Women's health (5)
Date
Today (1)
Last 7 days (17)
Last 30 days (70)
Last 365 days (1095)
2026 (88)
2025 (1134)
2024 (1241)
2023 (1403)
2022 (1529)
2021 (1582)
2020 (1330)
2019 (823)
2018 (686)
2017 (6714)
2016 (295)
2015 (561)
2014 (374)
2013 (220)
2012 (267)
2011 (464)
2010 (566)
Location
Africa (19)
Alabama (1)
Arizona (5)
Asia (1288)
Australia (145)
California (383)
Canada (89)
China (17)
Colorado (18)
Connecticut (21)
Delaware (11)
Europe (3160)
Florida (78)
Georgia (14)
Illinois (27)
India (1)
Indiana (22)
Japan (6)
Kansas (2)
Kentucky (2)
Louisiana (5)
Maine (6)
Maryland (50)
Massachusetts (230)
Michigan (9)
Minnesota (35)
Missouri (8)
Montana (1)
Nevada (24)
New Hampshire (7)
New Jersey (137)
New Mexico (1)
New York (73)
North Carolina (62)
Northern California (198)
Ohio (13)
Pennsylvania (100)
South America (45)
Southern California (155)
Tennessee (5)
Texas (45)
United States (1429)
Utah (16)
Virginia (2)
Washington D.C. (1)
Washington State (65)
Wisconsin (5)
22,025 Results for "168".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Optimi Health to Supply MDMA to MAPS Israel’s Clinical Trial for Trauma-Related PTSD
Approved multicenter study sponsored by Sheba Medical Center to compare group and individual MDMA-assisted therapy for 168 patients experiencing trauma-related PTSD
November 26, 2025
·
6 min read
Press Releases
AbelZeta Presents New Data on C-CAR168 for the Treatment of Autoimmune Diseases at LUPUS 2025
May 23, 2025
·
5 min read
Business
Santa Ana Bio Launches With $168M, Targets Autoimmune and Inflammatory Diseases
With Versant Ventures as a founding investor, Santa Ana Bio emerged from stealth Thursday with $168 million in combined Series A and B funding to support plans to have two programs in the clinic by next year.
June 13, 2024
·
2 min read
·
Tyler Patchen
Biotech Bay
Santa Ana Bio Launches With $168 Million to Advance Precision Medicines for Inflammatory Diseases
Santa Ana Bio, a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, emerged from stealth with $168 million in combined Series A and B funding.
June 13, 2024
·
6 min read
Press Releases
Endurance Bio Inc. Announces Selection of T-168 for Neuro-SysMed’s SLEIPNIR Platform Trial in Parkinson’s Disease
May 23, 2025
·
3 min read
Press Releases
AbelZeta Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for C-CAR168 for the Treatment of Refractory SLE, Including LN
May 27, 2025
·
3 min read
Press Releases
Caris Life Sciences Raises $168 Million in Private Capital from Leading Investors to Continue Platform Expansion
April 7, 2025
·
3 min read
Press Releases
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
May 2, 2025
·
7 min read
Press Releases
AbelZeta Presents Preclinical Data from Study of C-CAR168 for the Treatment of Autoimmune Diseases at ACR Convergence 2024
November 18, 2024
·
5 min read
Policy
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
Baudax Bio, Inc., a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromuscular Blocking Agents and an associated reversal agent, announced that U.S. Food and Drug Administration has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors.
September 28, 2023
·
4 min read
1 of 2,203
Next
